Who is sponsoring NCT05690373?

NCT05690373 is sponsored by The Archer-Daniels-Midland Company.

What drugs are being tested in NCT05690373?

Interventions in NCT05690373: Probiotic effect on influenza vaccine response.

What condition does NCT05690373 study?

NCT05690373 studies Vaccine Response.

Is NCT05690373 still recruiting?

NCT05690373 is currently completed. Last updated 24 August 2023.

Last reviewed 2023-08-24 · How we verify

NCT05690373: VERB

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Probiotics and Influenza Vaccination Response

Completed NA Last updated 24 August 2023

What this trial tests

NA trial testing Probiotic effect on influenza vaccine response in Vaccine Response in 100 participants. Completed in 30 June 2023.

Timeline

20 March 2023

Primary endpoint
30 June 2023

30 June 2023

Quick facts

Lead sponsor	The Archer-Daniels-Midland Company
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	100
Start date	20 March 2023
Primary completion	30 June 2023
Estimated completion	30 June 2023
Sites	1 location across Netherlands

Drugs / interventions tested

Probiotic effect on influenza vaccine response

Conditions studied

Vaccine Response — all drugs for Vaccine Response →

Sponsor

The Archer-Daniels-Midland Company

Who can join

Adults 16 to 65, any sex, with Vaccine Response. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Assess efficacy of oral ingestion of a probiotic product on immune function in a population of healthy adult men and women in a clinical vaccination study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Vaccine Response

Currently open trials in the same condition.

NCT06821100 — Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COV · Phase 1 · recruiting
NCT05801978 — Durability of Vaccine Responses · Phase 4 · recruiting
NCT05518500 — A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults · Phase 4 · recruiting

Other The Archer-Daniels-Midland Company trials

Trials by the same sponsor.

NCT06710392 — Efficacy of Two Enzyme Cocktails in Healthy Adults · NA · not yet recruiting
NCT06701604 — Changes in Amino Acid Absorption After Adding a Probiotic to an Acute Protein Feeding · NA · not yet recruiting
NCT05562739 — Pilot Study to Assess the Effect of a Postbiotic Blend on Moderate Self-reported Anxiety · NA · completed
NCT06103994 — Study to Assess the Effect of Multistrain Probiotic on the Immune Response to the Influenza Vaccination · NA · completed
NCT06047145 — Evaluation of Soy Isoflavones on Skin Ageing Parameters · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05690373 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Archer-Daniels-Midland Company
Last refreshed: 24 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05690373.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing